Progressive adoption of cryoablative therapy for breast fibroadenoma in community practice

Michael J. Edwards, Ralph Broadwater, Lorraine Tafra, Daleela Jarowenki, Charles Mabry, Peter Beitsch, Pat Whitworth, Robert C. Martin, Lori Oetting

Research output: Contribution to journalArticle

Abstract

Cryoablation is a recent technological advance and has been used for the percutaneous treatment of breast fibroadenomas. Herein, we provide a retrospective summary of the early experience from a nationwide group. We organized a national registry to document the community practice and adoption of an office-based system of cryoablation for breast fibroadenoma. Data were abstracted during the first 6 weeks after the procedure to assess acute outcome and potential complications. At 6-and 12-month follow-up intervals, additional data were collected regarding fibroadenoma resolution, cosmesis, and patient satisfaction. Fifty-three sites ablated 310 fibroadenomas. Early follow-up data on 256 lesions showed that the procedure was well tolerated with infrequent minor complications immediately after the procedure. At 6 and 12 months postprocedure, the remaining fibroadenoma volume progressively involuted.At both intervals, cosmesis was excellent, and patient satisfaction was rated high. An early community experience with office-based cryoablation of breast fibroadenomas is encouraging and comparable to the initial experience of high-volume tertiary centers. More follow-up is necessary to determine long-term results and residual mammographic changes.

Original languageEnglish (US)
Pages (from-to)221-224
Number of pages4
JournalAmerican Journal of Surgery
Volume188
Issue number3
DOIs
StatePublished - Sep 2004
Externally publishedYes

Fingerprint

Fibroadenoma
Breast
Cryosurgery
Patient Satisfaction
Therapeutics
Registries

Keywords

  • Breast
  • Cryoablation
  • Fibroadenoma

ASJC Scopus subject areas

  • Surgery

Cite this

Edwards, M. J., Broadwater, R., Tafra, L., Jarowenki, D., Mabry, C., Beitsch, P., ... Oetting, L. (2004). Progressive adoption of cryoablative therapy for breast fibroadenoma in community practice. American Journal of Surgery, 188(3), 221-224. https://doi.org/10.1016/j.amjsurg.2004.07.002

Progressive adoption of cryoablative therapy for breast fibroadenoma in community practice. / Edwards, Michael J.; Broadwater, Ralph; Tafra, Lorraine; Jarowenki, Daleela; Mabry, Charles; Beitsch, Peter; Whitworth, Pat; Martin, Robert C.; Oetting, Lori.

In: American Journal of Surgery, Vol. 188, No. 3, 09.2004, p. 221-224.

Research output: Contribution to journalArticle

Edwards, MJ, Broadwater, R, Tafra, L, Jarowenki, D, Mabry, C, Beitsch, P, Whitworth, P, Martin, RC & Oetting, L 2004, 'Progressive adoption of cryoablative therapy for breast fibroadenoma in community practice', American Journal of Surgery, vol. 188, no. 3, pp. 221-224. https://doi.org/10.1016/j.amjsurg.2004.07.002
Edwards, Michael J. ; Broadwater, Ralph ; Tafra, Lorraine ; Jarowenki, Daleela ; Mabry, Charles ; Beitsch, Peter ; Whitworth, Pat ; Martin, Robert C. ; Oetting, Lori. / Progressive adoption of cryoablative therapy for breast fibroadenoma in community practice. In: American Journal of Surgery. 2004 ; Vol. 188, No. 3. pp. 221-224.
@article{5ada775abffa4d8d92d1a36e057856ad,
title = "Progressive adoption of cryoablative therapy for breast fibroadenoma in community practice",
abstract = "Cryoablation is a recent technological advance and has been used for the percutaneous treatment of breast fibroadenomas. Herein, we provide a retrospective summary of the early experience from a nationwide group. We organized a national registry to document the community practice and adoption of an office-based system of cryoablation for breast fibroadenoma. Data were abstracted during the first 6 weeks after the procedure to assess acute outcome and potential complications. At 6-and 12-month follow-up intervals, additional data were collected regarding fibroadenoma resolution, cosmesis, and patient satisfaction. Fifty-three sites ablated 310 fibroadenomas. Early follow-up data on 256 lesions showed that the procedure was well tolerated with infrequent minor complications immediately after the procedure. At 6 and 12 months postprocedure, the remaining fibroadenoma volume progressively involuted.At both intervals, cosmesis was excellent, and patient satisfaction was rated high. An early community experience with office-based cryoablation of breast fibroadenomas is encouraging and comparable to the initial experience of high-volume tertiary centers. More follow-up is necessary to determine long-term results and residual mammographic changes.",
keywords = "Breast, Cryoablation, Fibroadenoma",
author = "Edwards, {Michael J.} and Ralph Broadwater and Lorraine Tafra and Daleela Jarowenki and Charles Mabry and Peter Beitsch and Pat Whitworth and Martin, {Robert C.} and Lori Oetting",
year = "2004",
month = "9",
doi = "10.1016/j.amjsurg.2004.07.002",
language = "English (US)",
volume = "188",
pages = "221--224",
journal = "American Journal of Surgery",
issn = "0002-9610",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Progressive adoption of cryoablative therapy for breast fibroadenoma in community practice

AU - Edwards, Michael J.

AU - Broadwater, Ralph

AU - Tafra, Lorraine

AU - Jarowenki, Daleela

AU - Mabry, Charles

AU - Beitsch, Peter

AU - Whitworth, Pat

AU - Martin, Robert C.

AU - Oetting, Lori

PY - 2004/9

Y1 - 2004/9

N2 - Cryoablation is a recent technological advance and has been used for the percutaneous treatment of breast fibroadenomas. Herein, we provide a retrospective summary of the early experience from a nationwide group. We organized a national registry to document the community practice and adoption of an office-based system of cryoablation for breast fibroadenoma. Data were abstracted during the first 6 weeks after the procedure to assess acute outcome and potential complications. At 6-and 12-month follow-up intervals, additional data were collected regarding fibroadenoma resolution, cosmesis, and patient satisfaction. Fifty-three sites ablated 310 fibroadenomas. Early follow-up data on 256 lesions showed that the procedure was well tolerated with infrequent minor complications immediately after the procedure. At 6 and 12 months postprocedure, the remaining fibroadenoma volume progressively involuted.At both intervals, cosmesis was excellent, and patient satisfaction was rated high. An early community experience with office-based cryoablation of breast fibroadenomas is encouraging and comparable to the initial experience of high-volume tertiary centers. More follow-up is necessary to determine long-term results and residual mammographic changes.

AB - Cryoablation is a recent technological advance and has been used for the percutaneous treatment of breast fibroadenomas. Herein, we provide a retrospective summary of the early experience from a nationwide group. We organized a national registry to document the community practice and adoption of an office-based system of cryoablation for breast fibroadenoma. Data were abstracted during the first 6 weeks after the procedure to assess acute outcome and potential complications. At 6-and 12-month follow-up intervals, additional data were collected regarding fibroadenoma resolution, cosmesis, and patient satisfaction. Fifty-three sites ablated 310 fibroadenomas. Early follow-up data on 256 lesions showed that the procedure was well tolerated with infrequent minor complications immediately after the procedure. At 6 and 12 months postprocedure, the remaining fibroadenoma volume progressively involuted.At both intervals, cosmesis was excellent, and patient satisfaction was rated high. An early community experience with office-based cryoablation of breast fibroadenomas is encouraging and comparable to the initial experience of high-volume tertiary centers. More follow-up is necessary to determine long-term results and residual mammographic changes.

KW - Breast

KW - Cryoablation

KW - Fibroadenoma

UR - http://www.scopus.com/inward/record.url?scp=4644370522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644370522&partnerID=8YFLogxK

U2 - 10.1016/j.amjsurg.2004.07.002

DO - 10.1016/j.amjsurg.2004.07.002

M3 - Article

C2 - 15450823

AN - SCOPUS:4644370522

VL - 188

SP - 221

EP - 224

JO - American Journal of Surgery

JF - American Journal of Surgery

SN - 0002-9610

IS - 3

ER -